Trade
Trading Type
Spot
Trade crypto freely
Alpha
Points
Get promising tokens in streamlined on-chain trading
Pre-Market
Trade new tokens before they are officially listed
Margin
Magnify your profit with leverage
Convert & Block Trading
0 Fees
Trade any size with no fees and no slippage
Leveraged Tokens
Get exposure to leveraged positions simply
Futures
Futures
Hundreds of contracts settled in USDT or BTC
Options
HOT
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
Investment
Simple Earn
VIP
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Quant Fund
VIP
Top asset management team helps you profit without hassle
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-Stop Lending Hub
VIP Wealth Hub
New
Customized wealth management empowers your assets growth
Staking
Stake cryptos to earn in PoS products
BTC Staking
HOT
Stake BTC and earn 10% APR
ETH Staking
HOT
Stake ETH and earn 6% APR
GUSD Minting
New
Use USDT/USDC to mint GUSD for treasury-level yields
Soft Staking
Earn rewards with flexible staking
More
- Trending TopicsView More
15.4K Popularity
33.4K Popularity
41.4K Popularity
36.1K Popularity
1.2K Popularity
- Pin
- 🌕 Gate Square · Creator Incentive Program Day 8 Topic– #XRP ETF Goes Live# !
Share trending topic posts, and split $5,000 in prizes! 🎁
👉 Check details & join: https://www.gate.com/campaigns/1953
💝 New users: Post for the first time and complete the interaction tasks to share $600 newcomer pool!
🔥 Day 8 Hot Topic: XRP ETF Goes Live
REX-Osprey XRP ETF (XRPR) to Launch This Week! XRPR will be the first spot ETF tracking the performance of the world’s third-largest cryptocurrency, XRP, launched by REX-Osprey (also the team behind SSK). According to Bloomberg Senior ETF Analyst Eric Balchunas, - 🚀 Gate $PUMP Futures Trading Challenge is Now Live!
Trade & check in daily to earn 370 USDT — join now: https://www.gate.com/campaigns/2001
Share a 50,000 USDT Prize Pool
🎯 Earn daily check-in rewards, deposit to claim airdrops, plus exclusive perks for all
Announcement link: https://www.gate.com/announcements/article/47104 - 🌕 Gate Square · Mid-Autumn Creator Incentive Program is Now Live!
Share your creations with trending topics and get a chance to split $5,000 in rewards! 🎁
👉 Join now: https://www.gate.com/campaigns/1953
💡 How to Join:
1️⃣ Post with the hashtag #Gate Square Mid Autumn Creator Incentive# .
2️⃣ Your content should follow the daily trending topics posted by [Gate _Square], and include both hashtags.
3️⃣ The more posts, higher quality, and greater engagement — the bigger your rewards! 🚀
💰 Creator Rewards:
🏆 Top 1: Bulgari Mid-Autumn Gift Box + $100 Futures Voucher + $100 GT
🥈 Top 2: Bulgari - 🚗 #GateSquareCommunityChallenge# Round 1 — Who Will Be The First To The Moon?
Brain challenge, guess and win rewards!
5 lucky users with the correct answers will share $50 GT! 💰
Join:
1️⃣ Follow Gate_Square
2️⃣ Like this post
3️⃣ Drop your answer in the comments
📅 Ends at 16:00, Sep 17 (UTC)
HSBC raises Sino Biopharmaceutical's target price to 58 Hong Kong dollars, with first-half revenue beating expectations
The September 16th data from Golden Ten shows that HSBC Global Research has released a report stating that Innovent Biologics (01801.HK) has exceeded the bank's and market expectations in the first half of the year, with promising prospects for PD-1 and IL-2, which can support business development opportunities. The buy rating is maintained, and the target price has been raised from 55 Hong Kong dollars to 58 Hong Kong dollars. The bank has raised its revenue forecast for 2024 to 2026 by 2 to 6%. HSBC Research expects Innovent Biologics' revenue from 2024 to 2026 to rise by 28 to 32%, reaching breakeven in 2025. Calculated at 8 times the 2024 price-to-sales ratio, breakeven is approaching, and with the launch of multiple innovative drugs from 2024 to 2025 as a catalyst, the valuation of Innovent Biologics is considered attractive.